Stock Events

Stock Events

Rani Therapeutics 

$0.77
98
+$0+0.38% Today

Statistics

Day High
0.79
Day Low
0.73
52W High
-
52W Low
-
Volume
121,662
Avg. Volume
-
Mkt Cap
74.72M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-0.15
-0.12
-0.08
-0.04
Expected EPS
-0.045
Actual EPS
N/A

Financials

-2,920.04%Profit Margin
Unprofitable
2021
2022
2023
2024
2.06MRevenue
-60.04MNet Income

Analyst Ratings

$10.50Average Price Target
The highest estimate is 11.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RANI.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Organogenesis
ORGO
Mkt Cap539.15M
Organogenesis offers regenerative medicines which compete with Rani's therapeutic approach in healing and regeneration.
Medtronic
MDT
Mkt Cap116.33B
Medtronic, with its extensive range of medical devices, competes in the broader healthcare solutions space, including drug delivery systems similar to Rani's.
Inspire Medical Systems
INSP
Mkt Cap2.13B
Inspire Medical Systems offers innovative healthcare solutions that can be seen as alternatives to drug therapies, indirectly competing with Rani's offerings.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals focuses on creating transformative medicines, potentially competing in the same therapeutic areas as Rani.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in the pharmaceuticals sector, developing drugs that could compete with Rani's therapeutic products.
AMGEN
AMGN
Mkt Cap160.66B
Amgen, a biotech firm, develops a wide range of treatments that could compete with Rani's drug delivery technology.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company with a broad product line that could compete with Rani's therapies.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk specializes in diabetes care but also ventures into biopharmaceuticals, making it a competitor in some therapeutic areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on rare disease treatments, potentially competing in niche markets targeted by Rani.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, known for its innovative medicines, competes in developing therapies that could overlap with Rani's market.

About

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Show more...
CEO
ISIN
US7530181004

Listings

XNAS
US
RANI
BOATS
BOATS
RANI.BOATS

0 Comments

Share your thoughts

FAQ

What is Rani Therapeutics stock price today?▼
The current price of RANI.BOATS is $0.77 USD — it has increased by +0.38% in the past 24 hours. Watch Rani Therapeutics stock price performance more closely on the chart.
What is Rani Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Rani Therapeutics stocks are traded under the ticker RANI.BOATS.
What is Rani Therapeutics market cap?▼
Today Rani Therapeutics has the market capitalization of 74.72M
When is the next Rani Therapeutics earnings date?▼
Rani Therapeutics is going to release the next earnings report on May 13, 2026.
What were Rani Therapeutics earnings last quarter?▼
RANI.BOATS earnings for the last quarter are -0.07 USD per share, whereas the estimation was -0.05 USD resulting in a -47.37% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Rani Therapeutics revenue for the last year?▼
Rani Therapeutics revenue for the last year amounts to 2.06M USD.
What is Rani Therapeutics net income for the last year?▼
RANI.BOATS net income for the last year is -60.04M USD.
When did Rani Therapeutics complete a stock split?▼
Rani Therapeutics has not had any recent stock splits.